Next Article in Journal
The Long Non-Coding RNA RP5-1024C24.1 and Its Associated-Gene MPPED2 Are Down-Regulated in Human Thyroid Neoplasias and Act as Tumour Suppressors
Next Article in Special Issue
The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes
Previous Article in Journal
Temozolomide Enhances Triple-Negative Breast Cancer Virotherapy In Vitro
Previous Article in Special Issue
Chromosomal Instability in Hodgkin Lymphoma: An In-Depth Review and Perspectives
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessReview
Cancers 2018, 10(5), 145; https://doi.org/10.3390/cancers10050145

[18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives

1
Nuclear Medicine Department, Institut Claudius Regaud, 31100 Toulouse, France
2
Centre de Recherches en Cancérologie de Toulouse (CRCT), UMR1037 INSERM, Université Toulouse III: Paul-Sabatier, ERL5294 CNRS, Université de Toulouse, 31100 Toulouse, France
3
Hématologie Clinique, CHU Dijon, 21000 Dijon, France
4
INSERM UMR1231, Université de Bourgogne Franche Comte, 21000 Dijon, France
*
Author to whom correspondence should be addressed.
Received: 9 April 2018 / Revised: 15 May 2018 / Accepted: 15 May 2018 / Published: 18 May 2018
(This article belongs to the Special Issue Hodgkin's Lymphoma)
Full-Text   |   PDF [509 KB, uploaded 18 May 2018]   |  

Abstract

Functional imaging using 18-fluorodeoxyglycose ([18F]FDG) positron emission tomography combined with computed tomography (PET/CT) has become a major imaging modality in Hodgkin lymphoma. This imaging modality allows for a significant improvement in staging, increased sensitivity, which involves differentiating residual tumors from fibrosis during assessment, and highly impacts treatment decisions into new PET-driven strategies. This review presents the main scientific data concerning the current applications of [18F]FDG-PET/CT in Hodgkin lymphoma at baseline, interim, and the end of treatment evaluation along with the main PET-driven trials for therapeutic decisions. The emergence of total metabolic tumor volume as a new functional prognostic factor will also be discussed. View Full-Text
Keywords: Hodgkin Lymphoma; [18F]FDG; PET/CT; staging; treatment response; interim PET; total metabolic tumor volume Hodgkin Lymphoma; [18F]FDG; PET/CT; staging; treatment response; interim PET; total metabolic tumor volume
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Kanoun, S.; Rossi, C.; Casasnovas, O. [18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives. Cancers 2018, 10, 145.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top